Additional research is required, but we cannot therefore rule out the possibility that precision therapy strategies based on NDP52 could become crucial in the development of drugs for AD, MS, CD, and possibly other inflammatory diseases linked to Tau accumulation such as postencephalitic parkinsonism [127], or the chronic traumatic encephalopathy [128]. The gene discussed is CALCOCO2; the disease is Alzheimer disease.